All articles tagged with #yeztugo
Gilead Sciences' new HIV prevention shot, Yeztugo, shows high efficacy but faces challenges in adoption due to its high $28,000 price tag, with CVS Caremark declining to include it in its formulary despite other insurers moving forward, raising concerns about affordability and disease eradication efforts in the U.S.
A new twice-yearly HIV prevention shot called Yeztugo has been approved by the FDA, offering a potentially more effective and easier alternative to daily pills for at-risk individuals, though concerns about cost and accessibility remain.
The FDA approved Gilead's twice-yearly HIV prevention injection, Yeztugo, which could significantly improve prevention efforts due to its convenience and high efficacy, but its impact may be hindered by potential federal funding cuts and access issues, especially among underserved populations.
The FDA has approved Yeztugo, a long-acting HIV prevention drug by Gilead Sciences, which is injected twice a year and shows high efficacy in preventing HIV transmission, especially among high-risk populations. Despite its potential, challenges such as high cost, insurance coverage issues, and political funding cuts could hinder its widespread use and impact on reducing HIV rates in the US.